ANIKA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.57 USD | -0.04% |
|
-1.04% | +12.84% |
| Mar. 14 | Barrington Ups Price Target on Anika Therapeutics to $37 From $29, Keeps Outperform Rating | MT |
| Mar. 13 | Transcript : Anika Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 739.9 | 643.3 | 517.3 | 432.4 | 331.8 | 374.9 | - | - |
| Enterprise Value (EV) 1 | 739.9 | 643.3 | 422.9 | 432.4 | 331.8 | 374.9 | 374.9 | 374.9 |
| P/E ratio | 27.4 x | -26.8 x | 128 x | -29 x | -4.02 x | -167 x | 61.9 x | 68.2 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 6.46 x | 4.93 x | 3.5 x | 2.77 x | 1.99 x | 2.2 x | 2.06 x | 1.93 x |
| EV / Revenue | 6.46 x | 4.93 x | 3.5 x | 2.77 x | 1.99 x | 2.2 x | 2.06 x | 1.93 x |
| EV / EBITDA | 15 x | 26.9 x | 31.5 x | 34.3 x | 21.4 x | 14.3 x | 12.4 x | 10.6 x |
| EV / FCF | 21.6 x | 56.3 x | 159 x | -141 x | - | 46.8 x | 27.7 x | 16.1 x |
| FCF Yield | 4.62% | 1.78% | 0.63% | -0.71% | - | 2.14% | 3.61% | 6.21% |
| Price to Book | - | - | 1.8 x | - | - | - | - | - |
| Nbr of stocks (in thousands) | 14,269 | 14,215 | 14,437 | 14,610 | 14,641 | 14,662 | - | - |
| Reference price 2 | 51.85 | 45.26 | 35.83 | 29.60 | 22.66 | 25.57 | 25.57 | 25.57 |
| Announcement Date | 2/20/20 | 3/4/21 | 3/8/22 | 3/6/23 | 3/13/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 114.6 | 130.5 | 147.8 | 156.2 | 166.7 | 170.3 | 181.8 | 193.9 |
| EBITDA 1 | 49.18 | 23.94 | 16.43 | 12.6 | 15.52 | 26.21 | 30.34 | 35.27 |
| EBIT 1 | 37.11 | -28.32 | 2.615 | -19.4 | -87.64 | -8.248 | 7.594 | 1.531 |
| Operating Margin | 32.38% | -21.71% | 1.77% | -12.42% | -52.58% | -4.84% | 4.18% | 0.79% |
| Earnings before Tax (EBT) 1 | 36.12 | -28.62 | 2.427 | -18.75 | -85.33 | -3.415 | 7.78 | 6.166 |
| Net income 1 | 27.19 | -23.98 | 4.134 | -14.86 | -82.67 | -2.211 | 6.064 | 5.596 |
| Net margin | 23.73% | -18.38% | 2.8% | -9.51% | -49.6% | -1.3% | 3.34% | 2.89% |
| EPS 2 | 1.890 | -1.690 | 0.2800 | -1.020 | -5.640 | -0.1533 | 0.4133 | 0.3750 |
| Free Cash Flow 1 | 34.18 | 11.44 | 3.254 | -3.077 | - | 8.019 | 13.52 | 23.29 |
| FCF margin | 29.82% | 8.77% | 2.2% | -1.97% | - | 4.71% | 7.44% | 12.01% |
| FCF Conversion (EBITDA) | 69.49% | 47.78% | 19.8% | - | - | 30.59% | 44.57% | 66.04% |
| FCF Conversion (Net income) | 125.69% | - | 78.71% | - | - | - | 222.98% | 416.25% |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/20/20 | 3/4/21 | 3/8/22 | 3/6/23 | 3/13/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 39.54 | 35.82 | 36.69 | 39.66 | 40.26 | 39.62 | 37.92 | 44.3 | 41.46 | 42.97 | 39.14 | 43.78 | 42.73 | 44.62 | 41.27 |
| EBITDA 1 | 5.747 | -0.199 | 2.608 | 4.42 | 4.05 | 1.375 | -1.204 | 6.272 | 4.65 | 5.798 | 4.442 | 7.945 | 7.068 | 6.758 | 6.092 |
| EBIT 1 | 1.3 | -9.123 | -3.554 | -3.381 | -5.798 | -6.667 | -12.55 | -3.631 | -7.674 | -63.78 | -5.635 | -0.53 | -1.422 | -0.6615 | -2.266 |
| Operating Margin | 3.29% | -25.47% | -9.69% | -8.53% | -14.4% | -16.83% | -33.1% | -8.2% | -18.51% | -148.43% | -14.4% | -1.21% | -3.33% | -1.48% | -5.49% |
| Earnings before Tax (EBT) 1 | 1.252 | -9.17 | -3.708 | -3.285 | -5.362 | -6.391 | -12.01 | -3.07 | -7.039 | -63.2 | -3.64 | 0.7633 | -0.3893 | -0.1493 | -0.8705 |
| Net income 1 | 0.558 | -5.793 | -2.933 | -2.843 | -4.175 | -4.908 | -10.35 | -2.741 | -6.576 | -63 | -2.708 | 0.7917 | -0.1963 | -0.099 | -0.6735 |
| Net margin | 1.41% | -16.17% | -7.99% | -7.17% | -10.37% | -12.39% | -27.29% | -6.19% | -15.86% | -146.61% | -6.92% | 1.81% | -0.46% | -0.22% | -1.63% |
| EPS 2 | 0.0400 | -0.4000 | -0.2000 | -0.2000 | -0.2900 | -0.3400 | -0.7100 | -0.1900 | -0.4500 | -4.300 | -0.1867 | 0.0567 | -0.0133 | -0.006670 | -0.0100 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/4/21 | 3/8/22 | 5/5/22 | 8/3/22 | 11/8/22 | 3/6/23 | 5/9/23 | 8/8/23 | 11/2/23 | 3/13/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | 94.4 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 34.2 | 11.4 | 3.25 | -3.08 | - | 8.02 | 13.5 | 23.3 |
| ROE (net income / shareholders' equity) | 10.7% | -8.55% | 1.48% | -5.19% | - | -3.2% | 5.5% | - |
| ROA (Net income/ Total Assets) | 9.66% | -6.89% | 1.16% | -4.27% | - | -2.5% | 4.4% | - |
| Assets 1 | 281.5 | 348.2 | 356.6 | 348.3 | - | 88.45 | 137.8 | - |
| Book Value Per Share | - | - | 19.90 | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 2.83 | 1.63 | 5.14 | 7.49 | - | 10.8 | 9.75 | 8 |
| Capex / Sales | 2.47% | 1.25% | 3.48% | 4.79% | - | 6.31% | 5.36% | 4.13% |
| Announcement Date | 2/20/20 | 3/4/21 | 3/8/22 | 3/6/23 | 3/13/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
25.57
USD
Average target price
30.33
USD
Spread / Average Target
+18.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.84% | 375M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- ANIK Stock
- Financials Anika Therapeutics, Inc.
